Generation Bio Stock Discussion

$Generation Bio (GBIO.US)$
Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases
Monday, 6th January at 4:30 pm
•Novel programs will combine validated cell-targeted LNP (ctLNP) delivery with siRNA to selectively modulate T cells in vivo
•Programs to focus on silencing hard-to-drug targets of high therapeutic value in T cell-driven autoimmune diseases
•Company reorganization supports evolution of ctLNP-enabled strategy and b...

$Generation Bio (GBIO.US)$ this one too

$Generation Bio (GBIO.US)$ hmm hmm

$Generation Bio (GBIO.US)$
NEWS
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
Positive
Generation Bio's presentation at the ASGCT highlights significant advancements in iqDNA technology and ctLNP delivery systems, showcasing the company's commitment to innovation in genetic medicine.
The rapid enzymatic synthesis process utilized by Generation Bio enhances the performance of iqDNA, providing a potential breakthrough in ...

$Generation Bio (GBIO.US)$
NEWS
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Generation Bio Co. will present six abstracts at the ASGCT 27th Annual Meeting.
The abstracts will highlight preclinical data from the company's ctLNP and iqDNA platforms.
One of the presentations will focus on highly specific, in vivo delivery to T-cells with cell-targeted lipid nanoparticles.
The c...